Liaoning Haisco Pharmaceutical Co., Ltd. was established on May 19, 2005, with a registered capital of RMB 780 million. In July 2011, it was recognized as a national high-tech enterprise covering an area of about 76,000 m2, and has built more than 50,000 m2 of various workshops and supporting facilities that meet the national GMP standards of China. The company has 8 professional production lines for such as small-volume injections (including pre-filled syringes), lyophilized powder for injection (including hormones), powder for injection (cephalosporins), large-volume injections (including multi-layer co-extrusion infusion bags), drug substances. Among them, the multi-chamber bag infusion production line with international advanced level has been constructed, and Medium and Long Chain Fat Emulsion, Amino Acid (16) and Glucose (16%) Injection has obtained the first (exclusive) approval for the production of multi-chamber bag infusion productions in China, and the product has been marketed at the end of 2018, filling the blank of domestic multi-chamber bag infusion.

The company has always been focusing on the development of new products, the marketed and developed products cover numbers of therapeutic areas such as anti-infection, digestive system, hematological system, nervous system, and parenteral nutrition. As of December 2020, Liaoning Haisco Pharmaceutical Co., Ltd. has obtained 39 drug production approval numbers for 28 varieties, including Compound Vitamin for Injection (3), Medium and Long Chain Fat Emulsion Injection (C8-24), Compound Amino Acid Injection (18AA-VII), Dorasetron Mesylate Injection, Fat Emulsion, Amino Acid (17) and Glucose (11%) Injection, Palonosetron Hydrochloride Injection, as well as five new drug certificates such as Nalmefene Hydrochloride Injection, Dorasetron Mesylate Injection, Compound Vitamin for Injection (3), and Arginine Glutamate Injection.